

CLAIMS

What is claimed is:

1. Use of at least one selective Farnesoid X receptor (FXR) agonist obtained from *Antrodia cinnamomea (Antrodia camphorate)* in the manufacture of a medicament for the treatment of at least one disease or disorder in a subject in need thereof, wherein a therapeutically effective amount of an extract of the at least one selective FXR agonist is to be administered to the subject, and wherein the administration enhances or induces FXR mediated transcriptional response in the subject, wherein the at least one FXR agonist is a triterpenoid compound selected from the group consisting of:



(I) and



(II) or

salts, solvates or tautomers thereof,

wherein the at least one disease or disorder is selected from obesity, diabetes, diarrhea, abdominal pain, hypertension, itchy skin, liver cancer, hepatitis, biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and fibrosis.

2. The use of claim 1, wherein the administration induces 60% to 85% of FXR activity in the absence of chenodeoxycholic acid (CDCA).

3. The use of claim 1, wherein the administration stimulates FXR activity by 15% to 30% in the presence of CDCA.

4. The use of claim 1, wherein the administration has no impact or insignificant impact on any other hormone receptor signaling pathway in the subject.


5. The use of claim 1, wherein the administration has no impact or insignificant impact on liver X receptor (LXR) mediated transcriptional response.


6. The use of claim 1, wherein the concentration of the triterpenoid is 10 μM to 85 μM.

7. The use of claim 1, wherein the subject is a mammal.

8. The use of claim 11, wherein the subject is human.

9. Use of a composition comprising at least one FXR agonist selected from the group consisting of





(I),


(II), and pharmaceutically acceptable salts, solvates, or tautomers thereof in the manufacture of a medicament for the treatment of at least one disease or disorder selected from the group consisting of obesity, diabetes, diarrhea, abdominal pain, hypertension, itchy skin, liver cancer, hepatitis, biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and fibrosis, wherein a therapeutically effective amount of the composition is to be administered to the subject.

10. The use of any one of claims 1 to 13, wherein the administration is by a route selected from the group consisting of intravenous, subcutaneous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.

11. A pharmaceutical composition for use in treating at least one disease or disorder selected from obesity, diabetes, diarrhea, abdominal pain, hypertension, itchy skin, liver cancer, hepatitis, biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and fibrosis, the pharmaceutical composition comprising at least one FXR agonist selected from the group consisting of



(I),


(II),

and pharmaceutically acceptable salts, solvates, or tautomers thereof; and

at least one pharmaceutically acceptable excipient,

wherein the composition comprises 0.0001% to 1% w/w of at least one triterpenoid compound from *Antrodia cinnamomea* that is not (I) or (II).

12. The pharmaceutical composition for use of claim 15, wherein the composition comprises a core comprising the at least one FXR agonist coated by the at least one pharmaceutically acceptable excipient or a matrix comprising the at least one FXR agonist interspersed with the at least one pharmaceutically acceptable excipient.